Russian Officials Steal Nearly $500 Million a Year From Cancer Drug Purchases

Russian officials, healthcare managers, and pharmaceutical distributors have built a corruption system that diverts hundreds of millions of dollars from state purchases of cancer and other expensive medicines, independent Russian investigative journalism outlet Proekt reported on November 2.

Proekt based its investigation on interviews with a former senior executive at an international pharmaceutical company, documents she provided, conversations with other industry figures, and Russian state procurement data. The investigation estimated that at least 10% to 20% of spending on costly medicines is diverted into bribes for hospital executives, officials, and security-service personnel.

“10–20% of every state purchase of expensive medicines in Russia goes to bribes for chief doctors, officials and security officials. That is hundreds of millions of dollars a year,” the former pharmaceutical executive, identified by Proekt as Antonina, stated. She claimed Western pharmaceutical companies effectively finance the payments through commercial bonuses paid to Russian distributors.

Proekt calculated that Russian healthcare institutions purchased nearly $500 million worth of corruption-linked excess spending in 2025 alone, based on the lower end of Antonina’s estimate. The investigation found that foreign drugmakers commonly return around 30% of a medicine’s value to Russian distributors as commercial bonuses, with bonuses on especially large tenders reaching as high as 60%.

According to the investigation, those bonuses create a pool of money that can be divided among major distributors, smaller intermediaries, and officials responsible for procurement decisions. Smaller regional companies often formally enter tenders instead of major distributors, helping preserve the appearance of competition while insulating larger companies from direct involvement in bribery allegations.

Read more

Category

Life in Ukraine

Ukraine Feeds 3 Million Schoolchildren for Free Despite Russian Attacks and Blackouts

Oct 11, 2026 16:43

Proekt reported that the system is particularly significant in oncology, where imported medicines account for some of Russia’s most expensive state purchases. Doctors and senior healthcare managers can influence which treatment protocols hospitals use, which medicines regions purchase, and how much authorities allocate to particular drugs, giving officials substantial leverage over procurement decisions.

The investigation also linked the pharmaceutical procurement system to businessmen with close connections to Russia’s political and security establishment. Proekt identified R-Pharm and Pharmstandard as major beneficiaries of the distributor-bonus model and described extensive business ties between pharmaceutical companies, government officials, security structures, and figures connected to the Russian leader Vladimir Putin.

Concerns over the system have previously reached US regulators. Proekt reported that complaints asking American authorities to investigate alleged corruption and tender collusion were submitted to the Securities and Exchange Commission and the Justice Department in 2024 and 2025, but enforcement efforts stalled after the Trump administration changed priorities for investigations under the Foreign Corrupt Practices Act.

The alleged corruption comes as Russia’s healthcare system faces widening budget cuts. More than three-quarters of Russian doctors surveyed across 74 cities reported healthcare spending cuts in their regions, while 46% reported that patients had been forced to buy medicines, dressings, or other basic medical supplies themselves in 2026.

Truth is Under Attack

We report the war as it unfolds directly from the people and places most affected by it. Your support helps us bring these stories to the world.

SUPPORT